Estimating the Morbidity of Robot-Assisted Radical Cystectomy Using the Comprehensive Complication Index: Data from the Asian Robot-Assisted Radical Cystectomy Consortium
<b>Background/Objectives</b>: The Clavien-Dindo classification (CDC) grades the most severe post-operative complication and may not comprehensively reflect cumulative surgical morbidity. Our objective was to investigate the potential incremental role of the comprehensive complication index (CCI) over the CDC in defining the quality of robot-assisted radical cystectomy (RARC). <b>Methods</b>: Data were extracted from the Asian RARC Consortium database. Complications were classified using the CCI (CCI = 0, CCI < 75th and ≥75th percentile) and CDC. Adverse peri-operative outcomes such as length of stay >14 days (LOS > 14 days), estimated blood loss >350 mL (EBL > 350 mL), time to solid food intake >4 days (TFI > 4 days) and 30-day readmission rates were analyzed. The area under the curve (AUC) of the receiver operating characteristic (ROC) curves for CCI and CDC were compared for the various adverse outcomes. <b>Results</b>: The peri-operative complication rate was 44.4%, comprising 11.6% with severe complications (CDC ≥ III). The mean CCI was 10.2 (±13.5) while median CCI was 0 (IQR 0-21). There were 7.6% of patients with >one perioperative complication. On adjusted analysis, CCI ≥ 75th percentile was significantly associated with greater LOS (>14 days) (OR 2.21, 95% CI 1.47-3.31, <i>p</i> < 0.001) compared to when CCI = 0. There were no significant differences in the AUC between CDC and CCI in predicting LOS > 14 days, TFI > 4 days, 30-day readmission or EBL > 350 mL. <b>Conclusions</b>: In our multi-institutional cohort, the CCI did not provide additional discrimination over CDC, and this is likely related to the limited number of complications that occurred per individual in the Asian RARC cohort. Hence, the perceived advantages of CCI over CDC are contextual.
Authors
- Shingo Hatakeyama (ORCID: https://orcid.org/0000-0002-0026-4079)
- Kittinut Kijvikai
- Satoru Muto (ORCID: https://orcid.org/0000-0002-5400-5195)
- Seok‐Ho Kang
- Haige Chen (ORCID: https://orcid.org/0000-0002-0582-5357)
- Jeremy Yuen‐Chun Teoh (ORCID: https://orcid.org/0000-0002-9361-2342)
- Raj Tiwari (ORCID: https://orcid.org/0000-0003-3893-5859)
- Chikara Οhyama (ORCID: https://orcid.org/0000-0003-1550-8379)
- Shigeo Horie (ORCID: https://orcid.org/0000-0002-8612-8368)
- Lui Shiong Lee (ORCID: https://orcid.org/0000-0002-8208-0635)
- Cheng‐Kuang Yang (ORCID: https://orcid.org/0000-0003-2235-3010)
- Manish I. Patel (ORCID: https://orcid.org/0000-0003-1409-9171)
- Thomas Y.K. Chan (ORCID: https://orcid.org/0009-0009-8691-2927)
- Eddie Chan
- Alvin Lee Yuanming
- Fiona Tan Bei Na
Institutions
- The University of Sydney (AU)
- Hirosaki University (JP)
- Chinese University of Hong Kong (HK)
- Shanghai Jiao Tong University (CN)
- Korea University (KR)
- Singapore General Hospital (SG)
- Mahidol University (TH)
- Renji Hospital (CN)
- Westmead Hospital (AU)
- Juntendo University (JP)
- Taichung Veterans General Hospital (TW)
- Ramathibodi Hospital (TH)
- Sengkang General Hospital (SG)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-29
- DOI
- https://doi.org/10.3390/cancers17071157
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01